 This phase II trial is studying how well fluorine F 18 sodium fluoride positron emission tomography PET works in evaluating response to dasatinib in patients with prostate cancer and bone metastases. Diagnostic procedures, such as fluorine F 18 sodium fluoride PET, may help doctors predict a patients response to treatment and help plan the best treatment. 